Download PDF
Dialyse aktuell 2011; 15(7): 378-383
DOI: 10.1055/s-0031-1289120
Nephrologie
© Georg Thieme Verlag Stuttgart · New York

Kardiorenales Anämiesyndrom – Was ist das?

CRAS – What is that?
Eberhard Ritz
Nierenzentrum Heidelberg e. V. (Geschäftsführer: Thomas Meyer)
› Author Affiliations
Further Information

Publication History

Publication Date:
09 September 2011 (online)

Also available at
    Permissions and Reprints

Der Begriff ”kardiorenales Anämiesyndrom“ weist auf die häufig vergesellschaftete, sich gegenseitig verstärkende, Beziehung zwischen eingeschränkter Herzfunktion, eingeschränkter Nierenfunktion und Anämie hin. Diese Klassifizierung ist nützlich, da sie Hinweise auf Therapieoptionen gibt, obwohl diese noch gegenwärtig sich nur teilweise auf kontrollierte Evidenz stützen können.

The term CRAS (”Cardiorenal Anemia Syndrome“) refers to the frequent coexistence of reduced cardiac function, reduced renal function and anemia. This classification is useful because it points to therapeutic options, although admittedly the evidence for the efficacy of this intervention is currently still incomplete.

Key words

CRAS - reduced cardiac function - reduced renal function - anemia - therapeutic options
 

  • Literatur

  • 1 Sandhu A, Soman S, Hudson M, Besarab A. Managing anemia in patients with chronic heart failure: what do we know?. Vasc Health Risk Manag 2010; 6: 237-252
    Google Scholar
  • 2 Felker GM, Shaw LK, Stough WG, O'Connor CM. Anemia in patients with heart failure and preserved systolic function. Am Heart J 2006; 151: 457-462
    CrossrefGoogle Scholar
  • 3 Young JB, Abraham WT, Albert NM et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol 2008; 101: 223-230
    CrossrefGoogle Scholar
  • 4 Tang WH, Tong W, Jain A et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2008; 51: 569-576
    CrossrefGoogle Scholar
  • 5 He SW, Wang LX. The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review. Congest Heart Fail 2009; 15: 123-130
    CrossrefGoogle Scholar
  • 6 Witte KK, Desilva R, Chattopadhyay S et al. Are hematinic deficiencies the cause of anemia in chronic heart failure?. Am Heart J 2004; 147: 924-930
    CrossrefGoogle Scholar
  • 7 Smith GL, Lichtman JH, Bracken MB et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987-1996
    CrossrefGoogle Scholar
  • 8 McClellan WM, Flanders WD, Langston RD et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002; 13: 1928-1936
    CrossrefGoogle Scholar
  • 9 Tanner H, Moschovitis G, Kuster GM et al. The prevalence of anemia in chronic heart failure. Int J Cardiol 2002; 86: 115-121
    CrossrefGoogle Scholar
  • 10 McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 2004; 15: 1912-1919
    CrossrefGoogle Scholar
  • 11 Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210
    CrossrefGoogle Scholar
  • 12 Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495
    CrossrefGoogle Scholar
  • 13 Silverberg DS, Wexler D, Iaina A, Schwartz D. The role of correction of anaemia in patients with congestive heart failure: a short review. Eur J Heart Fail 2008; 10: 819-823
    CrossrefGoogle Scholar
  • 14 Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 2003; 41: 1933-1939
    CrossrefGoogle Scholar
  • 15 Anand IS, Kuskowski MA, Rector TS et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005; 112: 1121-1127
    CrossrefGoogle Scholar
  • 16 Brucks S, Little WC, Chao T et al. Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol 2004; 93: 1055-1057
    CrossrefGoogle Scholar
  • 17 Adams Jr. KF et al. Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. Am Heart J 2009; 157: 926-932
    CrossrefGoogle Scholar
  • 18 Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 2005; 149: 391-401
    CrossrefGoogle Scholar
  • 19 Scrutinio D, Passantino A, Santoro D, Catanzaro R et al. The cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival. Eur J Heart Fail 2011; 13: 61-67
    CrossrefGoogle Scholar
  • 20 Muzzarelli S, Pfisterer M. TIME Investigators.. Anemia as independent predictor of major events in elderly patients with chronic angina. Am Heart J 2006; 152: 991-996
    CrossrefGoogle Scholar
  • 21 Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003; 107: 223-225
    CrossrefGoogle Scholar
  • 22 Levin A. The need for optimal and coordinated management of CKD. Kidney Int Suppl 2005; 99
    Google Scholar
  • 23 Collins AJ, Li S, Gilbertson DT et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003; 87
    Google Scholar
  • 24 Jie KE, Verhaar MC, Cramer MJ et al. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 2006; 291
    Google Scholar
  • 25 von Haehling S, Schefold JC, Hodoscek LM et al. Anaemia is an independent predictor of death in patients hospitalized for acute heart failure. Clin Res Cardiol 2010; 99: 107-113
    CrossrefGoogle Scholar
  • 26 Beck da Silva L, Rohde LE, Clausell N. Etiology and management of anemia in patients with heart failure: how much iron is missing?. Congest Heart Fail 2008; 14: 25-30
    Google Scholar
  • 27 Palazzuoli A, Silverberg D, Iovine F et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006; 152: 9-15
    Google Scholar
  • 28 Ghali JK, Anand IS, Abraham WT et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117: 526-535
    CrossrefGoogle Scholar
  • 29 van Veldhuisen DJ, Dickstein K, Cohen-Solal A et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007; 28: 2208-2016
    CrossrefGoogle Scholar
  • 30 Ponikowski P, Anker SD, Szachniewicz J et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007; 49: 753-762
    CrossrefGoogle Scholar
  • 31 Lawler PR, Filion KB, Eisenberg MJ. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents. J Card Fail 2010; 16: 649-658
    CrossrefGoogle Scholar
  • 32 Abraham WT, Anand IS, Klapholz M et al. Treatment of anemia with darbepoetin alfa in heart failure. Congest Heart Fail 2010; 16: 87-95
    CrossrefGoogle Scholar
  • 33 Palazzuoli A, Silverberg DS, Iovine F et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007; 154: 9-15
    Google Scholar
  • 34 Ponikowski P, Jankowska EA. EPO's rescue mission in acute myocardial infarction: still more hopes than evidence. Eur Heart J 2010; 31: 2577-2579
    CrossrefGoogle Scholar
  • 35 Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007
    Google Scholar
  • 36 Voors AA, Belonje AM, Zijlstra F et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010; 31: 2593-2600
    CrossrefGoogle Scholar
  • 37 Ozawa T, Toba K, Suzuki H et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study. Circ J 2010; 74: 1415-1423
    CrossrefGoogle Scholar
  • 38 Anker SD, Voors A, Okonko D et al. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. Eur Heart J 2009; 30: 1331-1339
    CrossrefGoogle Scholar
  • 39 Okonko DO, Grzeslo A, Witkowski T et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51: 103-112
    CrossrefGoogle Scholar
  • 40 Bolger AP, Bartlett FR, Penston HS et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48: 1225-1257
    CrossrefGoogle Scholar
  • 41 Jankowska EA, Rozentryt P, Witkowska A et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31: 1872-1880
    CrossrefGoogle Scholar
  • 42 Anker SD, Comin JColet, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448
    CrossrefGoogle Scholar
  • 43 McCullough PA. Prevention of cardiorenal syndromes. Contrib Nephrol 2010; 165: 101-111
    Google Scholar
  • 44 Attanasio P, Ronco C, Anker MS et al. Management of chronic cardiorenal syndrome. Contrib Nephrol 2010; 165: 129-139
    Google Scholar